Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-6007
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
mRNA-6007 is an investigational, off-the-shelf, in vivo chimeric antigen receptor T-cell (CAR-T) therapy being developed by Moderna. It consists of a multiplexed mRNA payload encapsulated within targeted lipid nanoparticles (LNPs) designed to target CD7, allowing specific delivery to CD4+ and CD8+ T cells as well as natural killer (NK) cells in vivo. Once inside, the cells transiently translate and express two distinct CARs targeting both CD19 (to cover the full B-cell lineage) and BCMA (to target antibody-secreting plasma cells). This dual-CAR approach aims to achieve deep and rapid depletion of pathogenic B cells and plasma cells to reset the immune system without the need for ex vivo cell manufacturing or lymphodepleting chemotherapy. mRNA-6007 is currently in preclinical development (IND-enabling studies) for the treatment of systemic lupus erythematosus (SLE) and other B-cell-mediated autoimmune diseases.
- Other names
- 007
02
Targets
Beyond the preview
Go deeper on mRNA-6007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-6007.